Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim

Michael D Tarantino, Scott Kolodny, Jessica Zhang, Brian Jamieson, Michael Vredenburg

Blood (2024) 144 (Supplement 1): 2560.

https://doi.org/10.1182/blood-2024-205489

Published: 2024

Journal Articles

Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses from a Prospective Phase 4 Study

Michael D Tarantino, Scott Kolodny, Michael Marrone, Brian Jamieson, Michael Vredenburg

Blood (2024) 144 (Supplement 1): 2559.

https://doi.org/10.1182/blood-2024-205466

Published: 2024

Journal Articles

Durability of Treatment Free Platelet Response in Children with Chronic Immune Thrombocytopenic Purpura Previously Treated with Romiplostim

Michael D Tarantino, Jessica Mistretta, Kristin T Ansteatt, Sarah Kreitzer, Dominique Barclay

Blood (2024) 144 (Supplement 1): 5434.

https://doi.org/10.1182/blood-2024-212020

Published: 2024

Journal Articles

Indirect Comparison of the Efficacy and Therapy-Related Costs of a Pharmacokinetic and Individualized Prophylaxis Regimen with Simoctocog Alfa Versus Other Extended-Half Life Factor VIII Concentrates

Craig Kessler, Fernando F Corrales-Medina, Pier Mannuccio Mannucci, Michael D Tarantino

Blood (2024) 144 (Supplement 1): 2592.

https://doi.org/10.1182/blood-2024-193880

Published: 2024

Journal Articles

Comparing BAT and Beighton Scores in Patients with ITP: A Retrospective Observational Cohort Study

Farrah N. Gaston, Dominique Barclay, Sarah Kreitzer, Michael D Tarantino

Blood (2024) 144 (Supplement 1): 5430.

https://doi.org/10.1182/blood-2024-211567

Published: 2024

Journal Articles

Interim Analysis of Platelet Response in a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA)

Michael D. Tarantino, Scott Kolodny, Jessica Zhang, Brian Jamieson, Michael Vredenburg

Blood (2023) 142 (Supplement 1): 2577.

https://doi.org/10.1182/blood-2023-189908

Published: 2023

Journal Articles

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Nichola Cooper, A.J. Gerard Jansen, Robert Bird, Jiří Mayer, Michelle Sholzberg, Michael D. Tarantino, Mamta Garg, Paula F Ypma, Vickie McDonald, Charles Percy, Milan Košťál, Isaac Goncalves, Lachezar H. Bogdanov, Terry B Gernsheimer, Remco Diab, Mengjie Yao, Ahmed Daak, David J Kuter

Blood (2023) 142 (Supplement 1): 685.

https://doi.org/10.1182/blood-2023-177808

Published: 2023

Journal Articles

The Effects of Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, on Bleeding Symptoms and Health-Related Quality of Life in Patients with Immune Thrombocytopenia

Michael D. Tarantino, A.J. Gerard Jansen, Nichola Cooper, Imene Gouia, Mengjie Yao, Ahmed Daak, David J Kuter

Blood (2023) 142 (Supplement 1): 690.

https://doi.org/10.1182/blood-2023-177811

Published: 2023

Journal Articles

Clinical Outcomes of Noninhibitor Patients with Hemophilia a Switching from Prophylaxis with Factor VIII to Emicizumab: A Meta-Analysis of Real-World Evidence Studies

Miguel A. Escobar, Qi Angela Fan, Ali G Mokdad, Michael D. Tarantino, Benjamin Burgess, Emma Hawe, Maria Fernandez, Michael Bullano

Blood (2023) 142 (Supplement 1): 283.

https://doi.org/10.1182/blood-2023-178007

Published: 2023

Journal Articles

Interim Analysis of Treatment Satisfaction from a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag or Romiplostim to Avatrombopag

Michael D. Tarantino, Scott Kolodny, Jessica Zhang, Brian Jamieson, Michael Vredenburg

Blood (2023) 142 (Supplement 1): 3954.

https://doi.org/10.1182/blood-2023-189224

Published: 2023

Journal Articles

Matching-Adjusted Indirect Comparison of Personalized Prophylaxis with Simoctocog Alfa Versus Standard Prophylaxis with Efanesoctocog Alfa in Adults with Severe Hemophilia a

Craig Kessler, Fernando F Corrales-Medina, Pier Mannuccio Mannucci, Michael D. Tarantino

Blood (2023) 142 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2023-180603

Published: 2023

Journal Articles

Prophylaxis and Treatment of Bleeding or Thrombosis with Fibrinogen Concentrate (Fibryga) in Patients with Congenital Hypofibrinogenemia or Dysfibrinogenemia

Michael D. Tarantino, Kristin Ansteatt, Jessica Mistretta

Blood (2023) 142 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2023-181045

Published: 2023

Journal Articles

Matching-Adjusted Indirect Comparison between Personalized Prophylaxis with Simoctocog Alfa Versus Standard Prophylaxis with Emicizumab in Adults with Hemophilia a

Craig Kessler, Fernando F Corrales-Medina, Pier Mannuccio Mannucci, Michael D. Tarantino

Blood (2023) 142 (Supplement 1): 5482.

https://doi.org/10.1182/blood-2023-180634

Published: 2023

Journal Articles

Atenativ, a Plasma-Derived Antithrombin Concentrate, Used in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Parturition: Study Description (NCT04918173)

Craig M. Kessler, Claudio Sandoval, Martina Jansen, Cristina Solomon, Sigurd Knaub, Michael D Tarantino

Blood (2022) 140 (Supplement 1): 8548–8549.

https://doi.org/10.1182/blood-2022-166246

Published: 2022

Journal Articles

Joint Status and Bleeding Phenotype Characterization in Severe and Non-Severe Hemophilia a and B

Jonathan C. Roberts, Sarah E Gonzales, Amanda M. Kilgore, Dominique N. Barclay, Michael D Tarantino

Blood (2022) 140 (Supplement 1): 8470–8471.

https://doi.org/10.1182/blood-2022-163636

Published: 2022

Journal Articles

Hereditary Antithrombin Deficiency Pilot Project Registry from the American Thrombosis and Hemostasis Network (ATHN)

Maria T DeSancho, Erin Suvar, Jonathan C. Roberts, Michael D Tarantino, Jarren Santos, Michael Recht

Blood (2022) 140 (Supplement 1): 5670–5672.

https://doi.org/10.1182/blood-2022-168179

Published: 2022

Journal Articles

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Eun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer DiRaimo, Terry Gernsheimer, Alexandra Kruse, Craig Kessler, Caroline Kruse, Andrew D. Leavitt, Alfred I. Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D. Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B. Bussel

Blood (2022) 139 (10): 1564–1574.

https://doi.org/10.1182/blood.2021013411

Published: 2022

Includes: Supplemental data

Journal Articles

LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia

David J. Kuter, James B Bussel, Nichola Cooper, Terry Gernsheimer, Michele P. Lambert, Howard Liebman, Michael D Tarantino, Olga Bandman, Puneet Arora, Ann Neale, Regan Burns, Mengjie Yao, Waleed Ghanima

Blood (2021) 138 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2021-144504

Published: 2021

Journal Articles

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

Eun-Ju Lee, Marina Beltrami Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer MacWhirter - DiRaimo, Terry B. Gernsheimer, Alexandra Kruse, Craig M. Kessler, Caroline Kruse, Andrew D Leavitt, Alfred Ian Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B Bussel

Blood (2021) 138 (Supplement 1): 586.

https://doi.org/10.1182/blood-2021-152918

Published: 2021

Journal Articles

Eculizumab for Refractory Thrombosis in Antiphospholipid Syndrome

Habiba Hussain, MD, Michael D Tarantino, MD, Keith R McCrae, MD, Shruti Chaturvedi, MBBS,MS, Jonathan C. Roberts, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-140535

Published: 2020

NARROW

Results of a Prospective, Open-Label, Phase 4 Study Evaluating the Safety, Efficacy, and Treatment Satisfaction in Adult Immune Thrombocytopenia (ITP) Subjects after Switching to Avatrombopag from Eltrombopag or Romiplostim

Enhanced Patient Satisfaction and Stability of Platelet Counts Following a Switch from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA) in Adult Idiopathic Thrombocytopenic Purpura (ITP): Post-Hoc Analyses from a Prospective Phase 4 Study

Durability of Treatment Free Platelet Response in Children with Chronic Immune Thrombocytopenic Purpura Previously Treated with Romiplostim

Indirect Comparison of the Efficacy and Therapy-Related Costs of a Pharmacokinetic and Individualized Prophylaxis Regimen with Simoctocog Alfa Versus Other Extended-Half Life Factor VIII Concentrates

Comparing BAT and Beighton Scores in Patients with ITP: A Retrospective Observational Cohort Study

Interim Analysis of Platelet Response in a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag (ELT) or Romiplostim (ROMI) to Avatrombopag (AVA)

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

The Effects of Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, on Bleeding Symptoms and Health-Related Quality of Life in Patients with Immune Thrombocytopenia

Clinical Outcomes of Noninhibitor Patients with Hemophilia a Switching from Prophylaxis with Factor VIII to Emicizumab: A Meta-Analysis of Real-World Evidence Studies

Interim Analysis of Treatment Satisfaction from a Prospective Phase 4 Study in Adult Immune Thrombocytopenia (ITP) Subjects after Switching from Eltrombopag or Romiplostim to Avatrombopag

Matching-Adjusted Indirect Comparison of Personalized Prophylaxis with Simoctocog Alfa Versus Standard Prophylaxis with Efanesoctocog Alfa in Adults with Severe Hemophilia a

Prophylaxis and Treatment of Bleeding or Thrombosis with Fibrinogen Concentrate (Fibryga) in Patients with Congenital Hypofibrinogenemia or Dysfibrinogenemia

Matching-Adjusted Indirect Comparison between Personalized Prophylaxis with Simoctocog Alfa Versus Standard Prophylaxis with Emicizumab in Adults with Hemophilia a

Atenativ, a Plasma-Derived Antithrombin Concentrate, Used in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Parturition: Study Description (NCT04918173)

Joint Status and Bleeding Phenotype Characterization in Severe and Non-Severe Hemophilia a and B

Hereditary Antithrombin Deficiency Pilot Project Registry from the American Thrombosis and Hemostasis Network (ATHN)

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

Eculizumab for Refractory Thrombosis in Antiphospholipid Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only